Introducing MARCo: Histoserological Findings of a Multi-Organic Paraneoplastic Syndrome in Cutaneous Melanoma Patients

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s13555-016-0142-5">https://link.springer.com/article/10.1007/s13555-016-0142-5</a></p> <p><br></p> <p><b>Provide enhanced content for this article</b></p> <p><br></p> <p>If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <a href="http://www.medengine.com/Redeem/”mailto:[email protected]”"><b>[email protected]</b></a>.</p> <p><br></p> <p>The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.</p> <p><br></p> <p>Other enhanced features include, but are not limited to:</p> <p><br></p> <p>• Slide decks</p> <p>• Videos and animations</p> <p>• Audio abstracts</p> <p>• Audio slides</p

Association between the presence of CTCs before starting a new line of chemotherapy and response to treatment.

<p>Higher response rate is observed in CTC-negative patients at baseline (A). Dynamic variation of CTCs numbers before and after treatment in patients (n = 10) with at least two determinations and at least one CTC at any time point. CTCs changes did not correlate with tumor response (B).</p

Patients characteristics at baseline.

<p>Patients characteristics at baseline.</p

Kaplan-Meier estimates of overall survival according to a combined risk factors model with Argiris factors and CTCs.

<p>Continuous line indicates absence of both risk factors; small dotted line indicates the presence of only one of the two risk factors; large dotted line indicates the presence of both risk factors.</p

Example of CTCs analysis in a patient with mediastinal and axillary nodal metastases from an oropharyngeal squamous cell carcinoma.

<p>(A) the CellSearch output of baseline CTC analysis showing two CTCs with heterogeneous EGFR expression. (B) Timeline of CTC analysis and treatments. (C) Correlative imaging analysis by CT/PET at baseline and after chemotherapy. In this patient 3 CTCs were detected at baseline. After 4 cycles of a chemotherapy, CTC number rised to 9 suggesting progressive disease then confirmed by CT/PET imaging.</p

Univariate associations between CTCs at baseline and clinico-pathologic characteristics.

<p>Univariate associations between CTCs at baseline and clinico-pathologic characteristics.</p

Appendix 1.docx

Appendix 1</p

Supplemental Table 1.docx

Supplemental Table</p

sj-docx-1-tam-10.1177_17588359231225028 – Supplemental material for Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry

Supplemental material, sj-docx-1-tam-10.1177_17588359231225028 for Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry by Bruno Vincenzi, Alessio Cortellini, Alessandro Mazzocca, Sarah Orlando, Davide Romandini, Juan Aguilar-Company, Isabel Ruiz-Camps, Claudia Valverde Morales, Simeon Eremiev-Eremiev, Carlo Tondini, Joan Brunet, Rossella Bertulli, Salvatore Provenzano, Mark Bower, Daniele Generali, Ramon Salazar, Anna Sureda, Aleix Prat, Michalarea Vasiliki, Mieke Van Hemelrijck, Ailsa Sita-Lumsden, Alexia Bertuzzi, Sabrina Rossi, Amanda Jackson, Federica Grosso, Alvin J. X. Lee, Cian Murphy, Katherine Belessiotis, Uma Mukherjee, Fanny Pommeret, Angela Loizidou, Gianluca Gaidano, Gino M. Dettorre, Salvatore Grisanti, Marco Tucci, Claudia A. M. Fulgenzi, Alessandra Gennari, Andrea Napolitano and David J. Pinato in Therapeutic Advances in Medical Oncology</p